Status:

COMPLETED

Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008)

Lead Sponsor:

Merck Sharp & Dohme LLC

Conditions:

Schizophrenia

Eligibility:

MALE

18-40 years

Phase:

PHASE1

Brief Summary

This study will assess transcranial magnetic stimulation (TMS) as a biomarker and characterize TMS readouts of the activity of MK2637 and dextromethorphan. Resting quantitative electroencephalography(...

Eligibility Criteria

Inclusion

  • Subject is right-handed
  • Subject is in good health
  • Subject is a nonsmoker

Exclusion

  • Subject works a night shift
  • Subject has a history of any illness that might make participation in the study unsafe or confound the study results
  • Subject has a history of head injury

Key Trial Info

Start Date :

July 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2009

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT00934466

Start Date

July 1 2009

End Date

December 1 2009

Last Update

June 24 2015

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008) | DecenTrialz